Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
No. 5 / 2025Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, ...
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...
The Manila Times5d
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...
Morningstar2d
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
manilatimes1d
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...
Yahoo Finance5d
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...